Piramal Pharma Limited (NSE:PPLPHARMA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Contract Development and Manufacturing Organisation	47.39B
Inhalation Anesthesia	16.42B
Inhalation Anesthesia Growth	13.25%
Intrathecal Therapy	3.68B
Intrathecal Therapy Growth	8.17%
Injectable Anesthesia and Pain Management	2.45B
Injectable Anesthesia and Pain Management Growth	-1.66%
Kids Wellness	2.26B
Kids Wellness Growth	20.63%
Other Generic and Specialty Products	1.96B
Other Generic and Specialty Products Growth	-13.46%
Skin Care	1.86B
Skin Care Growth	4.40%
Analgesic	1.86B
Multivitamin	1.47B
Other	2.35B
Other Growth	-51.42%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
North America	33.50B
North America Growth	5.13%
Europe	20.43B
Europe Growth	44.23%
India	16.34B
India Growth	15.39%
Japan	3.27B
Japan Growth	15.39%
Other	8.17B
Other Growth	4.90%